CLAIM #43215 · Merck & Company Inc (MRK) · 2022Q3 earnings call · Oct 27, 2022 · due Dec 31, 2030
“We remain very confident in our ability to protect more lives, to drive growth long into the future, including doubling the revenue of GARDASIL in the year 2030 compared to where we were in 2021.”
Caroline Litchfield · CFO
PENDING
graded after results covering Dec 31, 2030 are reported
How to check this claim
Look at: GARDASIL/GARDASIL 9 annual revenue (as reported in segment/product disclosures)
It came true if: Fiscal year 2030 GARDASIL revenue >= 2x fiscal year 2021 GARDASIL revenue
Where: Merck 10-K annual report, vaccines segment product revenue disclosure
Verify independently
SEC filings for MRK ↗ · Claim quote is verbatim from the 2022Q3 earnings call.